The Akt and Pim kinases are cytoplasmic serine/threonine kinases that control programmed cell death by phosphorylating substrates that regulate both apoptosis and cellular metabolism. The PI3K-dependent activation of the Akt kinases and the JAK/STAT–dependent induction of the Pim kinases are examples of partially overlapping survival kinase pathways. Pharmacological manipulation of such kinases could have a major impact on the treatment of a wide variety of human diseases including cancer, inflammatory disorders, and ischemic diseases.

Introduction

There is increasing evidence that serine/threonine kinases exist that directly regulate cell survival. Therapeutics that directly target these survival kinases have not yet been developed for clinical use. Activated survival kinases contribute to the pathogenesis of a wide variety of malignancies. In addition, reduced survival kinase signaling may contribute to organ damage following ischemic insults. Selective therapies such as imatinib (1) and gefitinib (2) elicit tumor cell death by indirect inactivation of survival kinases. Would direct inhibition of survival kinases result in better therapeutic efficacy? Alternatively, could therapies that activate survival kinases lead to better organ preservation in ischemic diseases? Many drug discovery programs have begun to develop lead compounds to address these questions. This Review will explore the potential risks and benefits of targeting survival kinases by outlining (a) Akt and Pim kinase action in malignancy, immunity, and vascular disease, (b) the common substrates that survival kinases share, (c) recent advances in the understanding of survival kinase regulation, and (d) investigational agents that target survival kinases.

Kinases that promote cell survival and control cell metabolism

For this Review survival kinases will be defined as cytoplasmic serine/threonine kinases that phosphorylate substrates that collectively contribute to the control of the programmed cell death machinery and cellular metabolism (Figure 1). This coordinated control ensures the maintenance of mitochondrial membrane potential and prevents the mitochondrial release of cytochrome c and other proapoptotic mediators. This coordinated control also maintains cellular ATP production, preventing cells from dying by necrosis (3) or autophagy (4). The best-characterized survival kinases were identified in screens to find suppressors of myc-induced apoptosis. myc is a protooncogene whose overexpression leads to increased proliferation as well as increased apoptosis in nonmalignant cells. Defects in pathways that control apoptosis prevent myc-induced apoptosis and allow myc to act as an oncogene, leading to a malignant phenotype. While deficiency in the tumor suppressor gene p53 and constitutive activation of the antiapoptosis gene bcl-2 are well characterized events that block myc-induced apoptosis, screens using retroviral mutagenesis have uncovered several serine/threonine kinases, including the Akt (5) and Pim (6) kinases, as potent suppressors of myc-induced apoptosis. As described below, these kinases coordinately regulate both apoptosis and cellular metabolism. The ability to reproducibly suppress the strong apoptotic stimulus of myc expression might serve as a criterion to identify other survival kinases.

Another characteristic of survival kinases is that they are activated by extracellular survival signals through cell surface receptors. Most receptors that can promote cell survival engage multiple signal transduction pathways. Many signaling pathways associated with activated receptor tyrosine kinases—including Src, phospholipase Cγ (PLCγ), and Ras/Raf/MEK/MAPK signaling—appear to promote cell survival. However, the central role of PI3K and Akt in receptor-mediated regulation of cell survival has been demonstrated in a variety of cell types. For example, in VSMCs expressing a number of PDGFR genes that are mutant for 1 or multiple binding sites necessary to activate the Src, Ras, PLCγ, or PI3K signaling pathways, growth factor–induced activation of PI3K/Akt signaling is the only kinase pathway that can prevent cell death induced by diverse stimuli when other kinase pathways are inactivated (7). These findings suggest that many kinase signaling pathways impact cell survival by direct or indirect contributions to PI3K/Akt signaling.

Another family of kinases that satisfies the criteria for survival kinases, and whose function does not appear to be dependent on PI3K/Akt signaling, is the Pim kinase family. The Pim kinases were originally implicated in cell survival by their ability to suppress myc-induced apoptosis in a mouse model of lymphoma (6, 8). Unlike the other serine/threonine kinases mentioned thus far, these kinases are not regulated by membrane recruitment or phosphorylation. The Pim kinases are unusual in that they are regulated primarily by transcription. Activated cytokine receptors recruit JAKs to induce STAT-dependent transcription of the Pim genes. While the role of Akt in promoting the survival of both normal and malignant cells is well established, the role of Pim signaling for cell survival in nontransformed cells has only recently been identified (9).

Although there are numerous pharmacological agents in preclinical and clinical development that can induce cell death by targeting other serine/threonine kinases, discussion of these...
will focus on the structure, activation, and pharmacological manipulation of kinases that promote cell survival through the PI3K/Akt and JAK/STAT/Pim pathways.

Structure and regulation of survival kinase activation

There are 8 mammalian isoforms of PI3K, separated into class IA, class IB, class II, and class III. Class I PI3Ks are the only kinases that generate phosphatidylinositol 3,4,5-triphosphate (PIP3). The most common form of class I PI3K associated with receptor tyrosine kinases is a heterodimer consisting of a p110 catalytic subunit and a p85 regulatory subunit. There are 3 p110 isoforms, p110α, p110β, and p110δ, the first 2 of which are widely expressed and the third of which is restricted to lymphocytes (10).

There are 3 isoforms of both Akt and Pim kinases, each encoded by distinct genes (Figure 1). The 3 Akt isoforms, Akt1, Akt2, and Akt3, share a highly conserved pleckstrin homology domain (PH) that binds to PIP3 at membrane surfaces, the kinase domain, and the regulatory domain. The 2 phosphorylation sites necessary for Akt activation are shown. The structures of human Pim-1, Pim-2, and Pim-3 demonstrate a conserved kinase domain and no regulatory domain. There are no required phosphorylation sites for Pim activation. Alternate start codons are depicted in Pim-2 leading to multiple Pim-2 isoforms that retain kinase activity.

The regulation of Akt is primarily posttranslational. Once translated, the Akt kinases bind to heat shock protein 90 (Hsp90), protecting the inactive Akt proteins from proteosomal degradation (12). Akt is recruited to the cell membrane through PIP3 produced by the lipid kinase activity of PI3K (for review see ref. 13). PI3K is directly associated with many cell surface growth factor and cytokine receptors, and upon ligand binding, PI3K activation generates PIP3. In addition to Akt, PIP3 recruits phosphoinositol-dependent kinase-1 (PDK1) and integrin-linked kinase (ILK) to the cell membrane. Generation of PIP3 is negatively regulated by the activity of phosphatase and tensin homolog (PTEN). PTEN deletion is the most common mechanism of inappropriate Akt activation in human malignancy (14). Akt activation requires 2 phosphorylation events: (a) PDK1 phosphorylation of Akt, and (b) phosphorylation of Akt by a kinase activity referred to as PDK2. Candidate kinases whose activities have been associated with PDK2 activity include ILK (15), DNA-dependent protein kinase (16), and PKCα (17, 18).

Recently, the rictor–mammalian target of rapamycin (rictor-mTOR) complex has been suggested as the major contributor to PDK2 kinase activity (19). While ILK activity may contribute to Akt-dependent cell survival, ILK has Akt-independent survival functions as well. Activation of ILK by the cytoplasmic kinase domains of integrin and growth factor receptors (20) maintains cell structure through its cytoskeletal binding partners. One PI3K-dependent survival kinase that does not phosphorylate Akt directly but augments the activity of Akt is the serum- and glucocorticoid-inducible kinase-1 (SGK1). SGK1 expression is regulated by the transcriptional activity of ligand-bound glucocorticoid receptor (21). In addition, diverse cellular insults such as osmotic stress, ultraviolet radiation, heat, and H2O2 result in induction of SGK1 expression (22). Although SGK1 does not require binding to PIP3, it is PI3K-dependent, because, like Akt, it depends on phosphorylation by PDK1 and PDK2 kinase activities for activation.

In contrast to the Akt kinases, the Pim kinases do not have a regulatory domain and, based on recent crystallography findings, are likely constitutively active when expressed (23). Pim kinase regulation occurs at the level of transcription, translation, and proteosomal degradation. In lymphocytes, upon cytokine engagement of its receptor, JAK phosphorylates and activates STAT proteins. Once phosphorylated, STATs translocate to the nucleus and serve as transcription factors for the Pim genes. In addition to transcriptional control, regulation of pim mRNA stability is also a determinant of Pim activity (24). Adding to the complexity of Pim regulation and activity is the fact that the gene for pim-2 encodes multiple proteins that have the same catalytic activity. Pim proteins are rapidly turned over by proteosomal degradation (25).

Survival kinases regulate common substrates

Once activated, the PI3K-dependent survival kinases and the Pim kinases phosphorylate common substrates that are involved in apoptosis and metabolism (Figure 2). Akt and Pim both directly phosphorylate and inactivate the proapoptotic Bcl-2 protein Bad (26–28). Both Akt and Pim kinases phosphorylate different components of proteins that are critical for maintaining a high rate of protein translation. For example, Akt phosphorylates TSC2, which controls mTOR activity, and mTOR and Pim kinases phosphorylate and inactivate the translational repressors (4EBP1. Akt and SGK1 act in concert to phosphorylate and inactivate FKHR1, a transcription factor that upregulates proapoptotic Bcl-2 proteins such as Bim and death receptor compo-
Survival kinases regulate cell death through the phosphorylation of common substrates of the apoptotic machinery and cellular metabolism. PI3K generates PIP$_3$, and PTEN converts PIP$_3$ back to PIP$_2$, negatively regulating PI3K signaling. PIP$_3$ recruits PDK1, ILK, and Akt to the cell membrane. PDK1, ILK, and the rictor-mTOR complex are important for the activation of Akt. Expression of both SGK1 and Pim kinases is inducible. Akt, SGK1, and Pim kinases share common substrates of the apoptosis machinery and cellular metabolism, depicted as color-coded overlapping boxes (see text for full description). PFK2, phosphofructokinase-2.

In addition to these common substrates, Akt has the potential to inactivate 3 pathways of apoptosis initiation: (a) p53-mediated apoptosis, by phosphorylation and activation of MDM2, a protein that binds p53 and facilitates its degradation (35); (b) mitochondrial-dependent apoptosis, by phosphorylation and inactivation of caspase-9 (36) and Bad, and phosphorylation and stabilization of the antiapoptotic protein XIAP (37); and (c) death receptor-mediated apoptosis, by inhibition of the Forkhead family of transcription factors (38). Akt directly controls cellular metabolism by maintaining the association of hexokinase with mitochondria (39) and by phosphorylating and activating ATP-citrate lyase and phosphofructokinase-2 (40). Akt controls the translation of nutrient transporters through the activation of mTOR (41), and the localization of glucose transporters to the plasma membrane (42).

A number of drugs have emerged that target pathways downstream of both Akt and Pim signaling. One example is bortezomib, which inhibits proteasome function, leading to the inhibition of NF-κB, and is now used for multiple myeloma (43). Rapamycin derivatives, which inhibit mTOR, are now being developed for treatment of a broad range of solid tumor malignancies. Strategies such as RNA interference could be used to further validate other survival kinase substrates as pharmacological targets.
Pharmacological inhibition of survival kinases

The problem of multiple isoforms: PI3K and Akt. Class I PI3K inhibitors such as wortmannin and LY294002 (Table 1) compete at the ATP binding site of the lipid kinase catalytic domain of all PI3Ks. Although these inhibitors have shown some efficacy in xenograft tumor models, they have not been developed for clinical use because of the broad specificity of kinase inhibition, poor pharmacokinetics, and relatively weak inhibition (44). Moreover, the recent finding that LY294002 binds and inhibits the activity of Pim-1 suggests that LY294002 can no longer be considered a selective tool to study PI3K-dependent biology. Currently a number of initiatives are under way that have identified isoform-selective ATP-competitive inhibitors of the PI3K. A potential validation of PI3K as a targetable survival kinase comes in the form of IC87114, an ATP-competitive inhibitor of the PI3K. A potential validation of PI3K as a targetable survival kinase comes in the form of IC87114, because of issues of toxicity. Concerns have been raised about Akt's isoform-selective Akt inhibitors. A series of pyridine derivatives were found to selectively inhibit Akt1, or Akt1 and Akt2, by binding to the pleckstrin homology domain (55). Currently, no Akt3-specific inhibitors have been reported.

Single-isoform survival kinases PDK1, ILK, and mTOR. PDK1 is a PI3K-dependent kinase that has been identified as the target of numerous inhibitors. Staurosporine analogs UCN-01 and CPG41251 inhibit PDK1, among other kinases, and have entered phase I cancer trials (56). Another example of an effective multi-target drug class that inhibits PDK1 is NSAIDs. NSAIDs such as sulindac (57) and celecoxib (58), a selective COX-2 inhibitor, were found to have the ability to induce apoptosis in colon cancer cells through inhibition of PDK1. A chemoprevention trial demonstrated that celecoxib reduced the incidence of polyp formation in patients with familial adenomatous polyposis (59). Unfortunately, further clinical evaluation of NSAIDs as chemopreventatives will require caution. An increased incidence of myocardial infarction and stroke in trial participants taking rofecoxib and high-dose celecoxib led to a moratorium on new chemopreventative trials with coxibs (COX-2 inhibitors) (60). Although the mechanism of increased thrombosis induced by COX-2 inhibitors remains unknown, many believe it is a COX-dependent phenomenon,

<table>
<thead>
<tr>
<th>Drug</th>
<th>Target(s)</th>
<th>Level of evidence</th>
<th>Comments</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>ATP-competitive inhibitors</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LY294002</td>
<td>PI3K, CK2, Pim-1</td>
<td>Mouse xenograft model</td>
<td>Broad specificity</td>
<td>43, 73</td>
</tr>
<tr>
<td>Wortmannin</td>
<td>PI3K</td>
<td>Mouse xenograft model</td>
<td>Short half-life</td>
<td>43</td>
</tr>
<tr>
<td>Methylxanthines</td>
<td>p110b (PI3K)</td>
<td>Theophylline used in humans</td>
<td>Weak isoform-specific inhibitor</td>
<td>43</td>
</tr>
<tr>
<td>IC87114</td>
<td>p110b (PI3K)</td>
<td>Prevents anaphylaxis in mice</td>
<td>Isoform-specific PI3K inhibitor</td>
<td>44</td>
</tr>
<tr>
<td>NSAIDs: sulindac, celecoxib</td>
<td>PD1K</td>
<td>Prevents colonic polyps in FAP</td>
<td>Trials terminated because of cardiovascular events</td>
<td>56–59</td>
</tr>
<tr>
<td>OSU-03012</td>
<td>PD1K</td>
<td>Human cancer cell lines</td>
<td>Coxib derivative with no anti-COX2 activity</td>
<td>60, 61</td>
</tr>
<tr>
<td>UCN-01</td>
<td>PDK1, CHK1, others</td>
<td>Human phase I trials</td>
<td>Staurosporine analog</td>
<td>55</td>
</tr>
<tr>
<td>KP-392</td>
<td>ILK</td>
<td>Mouse xenograft models</td>
<td>Antiangiogenic effect</td>
<td>66</td>
</tr>
<tr>
<td>AG490</td>
<td>JAK2</td>
<td>Mouse xenograft models</td>
<td>Synergy with imatinib</td>
<td>84</td>
</tr>
<tr>
<td>Non–ATP-competitive inhibitors</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>API-2 (triciribine)</td>
<td>Akt1, Akt2, Akt3</td>
<td>Human cancer trials in 1980s</td>
<td>Caused hyperglycemia, hepatotoxicity, revisited at a lower dose</td>
<td>47</td>
</tr>
<tr>
<td>Pyridine derivatives</td>
<td>Akt1, Akt2, Akt1/2</td>
<td>Apoptosis in cancer cell lines</td>
<td>Akt1 and Akt2 both need to be inhibited</td>
<td>54</td>
</tr>
<tr>
<td>Perifosine</td>
<td>Akt</td>
<td>Phase II trials in breast cancer</td>
<td>Severe gastrointestinal side effects may be limiting</td>
<td>48–50</td>
</tr>
<tr>
<td>Rapamycin derivatives</td>
<td>mTOR</td>
<td>Phase II/III trials in multiple malignancies</td>
<td>Antitumor activity at low doses</td>
<td>67</td>
</tr>
<tr>
<td>Cucurbitacin I</td>
<td>JAK/STAT3</td>
<td>Mouse xenograft model</td>
<td>Natural product</td>
<td>78</td>
</tr>
</tbody>
</table>

A summary of some reported kinase inhibitors, their specificity, and their current role as research tools or therapeutics. CK2, casein kinase II; FAP, familial adenomatous polyposis.
opening the door for coxib-derived molecules that more selectively target PDK1 and not the COX enzymes. Recently, a coxib derivative, OSU-03012, which has no activity against COX enzymes, was found to inhibit PDK1/Akt activity in prostate cancer cells (61) and sensitize imatinib-resistant BCR-ABL clones to imatinib (62).

ILK, another PI3K-dependent kinase implicated in the activation of Akt, has been found to play an important role in malignant pathogenesis. Overexpression of ILK correlates with the clinical stage of many epithelial neoplasms (63–65). The importance of pathogenesis. Overexpression of ILK correlates with the clinical stage of many epithelial neoplasms (63–65). The importance of targeting ILK is further supported by the finding that ILK activity is essential for VEGF-dependent tumor angiogenesis (66). Two small-molecule inhibitors of ILK activity have been identified and are currently being developed for clinical trials (67).

While the rictor-mTOR complex responsible for Akt phosphorylation is rapamycin-insensitive, rapamycin-sensitive mTOR activity contributes to Akt-dependent cell survival. Rapamycin and the rapamycin derivatives CCI-779, RAD001, and AP23573 are currently in multiple phase II and phase III clinical trials for both solid tumors and hematological malignancies (68) and have been found to be most effective in tumors with PTEN deletion or Akt activation; this suggests that mTOR inhibitors act to suppress rapamycin activity for postinfarct remodeling could be a promising strategy. The empirical benefit of glucocorticoids, such as prednisone or dexamethasone, seen in a variety of diseases involving epithelial injury may in fact be an unappreciated example of this strategy. In addition to suppression of an exuberant immune response, glucocorticoid activation of SGK1 in epithelial cells may contribute to organ preservation in scenarios such as radiation injury.

In contrast to pharmacological activation of survival kinases, pharmacological inhibition of protein phosphatases could be another fruitful strategy for organ preservation. Inhibition of PTEN or PP2A could be a means of activating Akt pharmacologically. Phosphatase structure and regulation are complex, however. Recently, ε4, a noncatalytic subunit of PP2A, was shown to be essential for cell survival, which suggests that certain conformations of phosphatase activity can mimic survival kinase function (82). Further consideration of the regulation of protein phosphatases is required before they can be pursued as therapeutic targets.

Finally, the PPARs are intriguing candidates for inducing Akt activation. PPARγ/δ was recently shown to coordinately upregulate PDK1 and ILK while downregulating expression of PTEN in keratinocytes, which implicates this nuclear receptor as an Akt regulator (83). Currently, selective PPARγ/δ agonists such as GW1505 are being developed for treatment of mucosal injury.

Conclusions

Recent advances in survival kinase structure and regulation have identified many potential targets for novel agents that can pharmacologically manipulate cell death. In turn, the basic understanding of the complexities of PI3K/Akt signaling with relation to cell survival will be enriched by the emergence of a new generation of more specific kinase inhibitors. The role of Pim kinases in cell survival will be better understood with the development of specific inhibitors. Evidence already exists to suggest that inhibitors of survival kinases can contribute to cancer therapy. Therapies designed to activate survival kinases may also be useful in preventing organ damage following injury. As our understanding of programmed cell death evolves, additional kinases that contribute to the regulation of cell survival will undoubtedly emerge.

Acknowledgments

We thank Casey Fox and Peter Hammerman for numerous helpful comments. R. Amaravadi is supported by NIH grant R25-CA87812.

Address correspondence to: Craig B. Thompson, University of Pennsylvania, Abramson Family Cancer Research Institute, 421 Cune Boulevard, Room 450 BRB II/III, Philadelphia, Pennsylvania 19104-6160, USA. Phone: (215) 746-5527; Fax: (215) 746-5511; E-mail: craig@mail.med.upenn.edu.


